Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,466 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid-related Disorders Clear all
Completed Not applicable Interventional Results available

The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky

NCT03725332
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Telemedicine, Group Care
Behavioral
Lead sponsor
Wendy F Hansen
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
11
States / cities
Ashland, Kentucky • Bowling Green, Kentucky • Corbin, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 14, 2026, 9:36 PM EDT
Not yet recruiting Not applicable Interventional

Deep Transcranial Magnetic Stimulation for Tobacco Cessation in Adults With Opioid Use Disorder

NCT07770555
View directory record Official record
Conditions
Opioid Use Disorder, Tobacco Use Disorder
Interventions
Deep TMS System With H4 Coil
Device
Lead sponsor
Payel Roy
Other
Eligibility
22 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Aging Through Movement

NCT05772884
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Supervised Exercise Intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Results available

Reward-Based Recovery Outcomes Management for Opioid Use Disorder

NCT04669249
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PROCare
Behavioral
Lead sponsor
Medical Decision Logic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 14, 2026, 9:36 PM EDT
Completed No phase listed Observational

Effects of Environmental Factors on Opiate Drug Choice in Opioid Dependent Individuals.

NCT00608504
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 14, 2026, 9:36 PM EDT
Terminated Phase 1 Interventional

Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder

NCT03143543
View directory record Official record
Conditions
Cocaine-Related Disorders, Opioid-Related Disorders
Interventions
Group A Lorcaserin (10mg), Group A2 Lorcaserin (20 mg), Group B Parallel Placebo, Group B2 Parallel Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 55 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

NCT02617628
View directory record Official record
Conditions
Opiate Dependence
Interventions
extended release naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

NCT04134767
View directory record Official record
Conditions
Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis), Overdose, Drug, Opioid Use
Interventions
Health Linkage, Overdose Education
Behavioral
Lead sponsor
April M Young
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9

NCT00000344
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 4 Interventional Results available

Counseling for Primary Care Office-based Buprenorphine

NCT00595764
View directory record Official record
Conditions
Opiate Dependence
Interventions
Manual-guided Physician Management (PM), Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China

NCT00757744
View directory record Official record
Conditions
Opiate Dependence, HIV Infections
Interventions
Behavioral Drug and HIV Risk Reduction Counseling (BDRC), Drug counseling
Behavioral
Lead sponsor
Yale University
Other
Eligibility
20 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CAM2038, Buprenorphine Sublingual Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Oakland, California • San Leandro, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 14, 2026, 9:36 PM EDT
Active, not recruiting Phase 3 Interventional

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl

NCT06089707
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naloxone Nasal Spray
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STEPuP: Prenatal Provider Education and Training to Improve Medication-assisted Treatment Use During Pregnancy

NCT04527926
View directory record Official record
Conditions
Opioid-use Disorder, Pregnancy Related
Interventions
STEPuP Intervention, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 14, 2026, 9:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone

NCT00000243
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 14, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional

Study of Probuphine in Patients With Opioid Dependence

NCT00772785
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant)
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 14, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals

NCT03711318
View directory record Official record
Conditions
Heroin Dependence
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 14, 2026, 9:36 PM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2010 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Not applicable Interventional Results available

Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II

NCT02411357
View directory record Official record
Conditions
Contraceptive Usage, Opioid Dependence
Interventions
Treatment as usual, WHO contraception protocol, Incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 14, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219
View directory record Official record
Conditions
Opioid-induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
115
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 14, 2026, 9:36 PM EDT